Therapy of Parkinson's disease Part 2: New therapeutic concepts for treating locomotor symptoms;Therapie des Morbus Parkinson Teil 2: Neue Therapiekonzepte fur die Behandlung motorischer Symptome

Fortschritte der Neurologie Psychiatrie

Volumn 65, Issue 8, 1997, Pages 375-385

  Kuhn, W ^a   Muller Th ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDIPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; NEUROPROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; THREO 3,4 DIHYDROXYPHENYLSERINE;

ARTICLE; DRUG RESEARCH; HUMAN; NEUROPROTECTION; NEUROSURGERY; PARKINSON DISEASE; STEREOTAXIC SURGERY;

EID: 0030964599     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996342     Document Type: Article

References (163)

1. Anonymous: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N. Engl. J. Med. 328 (1993) 176-183
2. Anonymous: Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann. Neurol. 39 (1996) 37-45
3. Aebischer, P., Tresco, P. A., Sagen, J., Winn, S. R.: Transplantation of microencapsulated bovine chromaffin cells reduces lesion-induced rotational asymmetry in rats. Brain Res. 560 (1991 a) 43
4. Aebischer, P., Winn, S. R., Tresco, P. A., Jaeger, C. B., Greene, L. A.: Transplantation of polymer encapsulated neurotransmitter secreting cells: effect of the encapsulation technique. J. Biomech. Eng. 113 (1991 b) 178-183
5. Arevalo, G. J., Gershanik, O. S.: Modulatory effect of clozapine on levodopa response in Parkinson's disease: A preliminary study. Mov. Disord. 8 (1993) 349-354
6. Bakay, R. A., Delong, M. R., Vitek, J. L.: Posteroventral pallidotomy for Parkinson's disease. J. Neurosurg. 77 (1992) 487-488
7. Baldessarini, R. J., Frankenburg, F. R.: Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324 (1991) 746-754
8. Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., Hefti, F.: Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373 (1995) 339-341
9. Benabid, A. L., Pollak, P., Gervason, C., Hoffmann, D., Gao, D. M., Hommel, M., Perret, J. E., de Rougemont, J.: Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337 (1991) 403-406
10. Benabid, A. L., Pollak, P., Seigneuret, E., Hoffmann, D., Gay, E., Perret, J.: Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochir. Suppl. Wien. 58 (1993) 39-44
11. Benabid, A. L., Pollak, P., Gross, C., Hoffmann, D., Benazzouz, A., Gao, D. M., Laurent, A., Gentil, M., Perret, J.: Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact. Funct. Neurosurg. 62 (1994) 76-84
12. Bennett, J. P., Jr., Landow, E. R., Schuh, L. A.: Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 43 (1993) 1551-1555.
13. Bennett, J. P., Jr., Landow, E. R., Dietrich, S., Schuh, L. A.: Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov. Disord. 9 (1994) 409-414
14. Birkmayer, J. G., Vrecko, C., Volc, D., Birkmayer, W.: Nicotinamide adenine dinucleotide (NADH) - A new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol. Scand. Suppl. 146 (1993) 32-35
15. Birkmayer, W., Knoll, J., Riederer, P., Youdim, M. B., Hars, V., Marton, J.: Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: A longterm study. J. Neural Transm. 64 (1985) 113-127
16. Birkmayer, W., Birkmayer, G. J.: Nicotinamide adenine dinucleotide (NADH): The new approach in the therapy of Parkinson's disease. Ann. Clin. Lab. Sci. 19 (1989a) 38-43
17. Birkmayer, W., Birkmayer, G. J., Vrecko, K., Mlekusch, W., Paletta, B., Ott, E.: The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of Parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 1 (1989b) 297-302
18. Birkmayer, W., Birkmayer, J. G., Vrecko, K., Paletta, B.: The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients. Adv. Neurol. 53 (1990) 545-549
19. Bonnet, A. M., Loria, Y., Saint Hilaire, M. H., Lhermitte, F., Agid, Y.: Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 37 (1987) 1539
20. Borlongan, C. V., Cahill, D. W., Freeman, T. B., Sanberg, P. R.: Recent advances in neural transplantation. Relevance to neurodegenerative disorders. J. Fla. Med. Assoc. 81 (1994) 689-694
21. Bowman, C. E.: Drug-licensing anomalies and Parkinson's disease. Lancet 345 (1995) 517
22. Braak, H., Braak, E., Yilmazer, D., de Vos, R. A. I., Jansen, E. N. H.: Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 46 (1995) 15-32
23. Breeze, R. E., Wells, T. H., Jr., Freed, C. R.: Implantation of fetal tissue for the management of Parkinson's disease: a technical note. Neurosurgery 36 (1995) 1044-1047
24. Broggi, G., Pluchino, F., Gennari, L., Geminiani, S., Tamma, F., Caraceni, T.: Adrenal medulla autograft in caudate nucleus as treatment for Parkinson's disease. Acta Neurochir. Suppl. Wien. 52 (1991) 45-47
25. Cedarbaum, J. M., Leger, G., Guttman, M.: Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease. Clin. Neuropharmacol. 14 (1991) 330-342
26. Cotman, C. W., Anderson, A. J.: A potential role for apoptosis in neurodegeneration and Alzheimer's disease. Mol. Neurobiol. 10 (1995) 19-45
27. Da Prada, M., Borgulya, J., Napolitano, A., Zürcher, G.: Improved therapy of Parkinson's disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methiomine sparing effect. Clin. Neuropharmacol. Suppl 17(3) (1994) 26-37
28. Davis, T. L., Roznoski, M., Burns, R. S.: Effects of tolcapone in Parkinson patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov. Disord. 10 (1995) 349-351
29. Diederich, N., Keipes, M., Graas, M., Metz, H.: Clozapine in the treatment of mental manifestations of Parkinson's disease. Rev. Neurol. Paris. 151 (1995) 251-257
30. Dingemanse, J., Jorga, K. M., Schmitt, M., Gieschke, R., Fotteler, B., Zurcher, G., Da Prada, M., van Brummelen, P.: Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57 (1995) 508-517
31. Dizdar, N., Kagedal, B., Lindvall, B.: Treatment of Parkinson's disease with NADH. Acta Neurol. Scand. 90 (1994) 345-347
32. Dogali, M., Fazzini, E., Kolodny, E., Eidelberg, D., Sterio, D., Devinsky, O., Beric, A.: Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 45 (1995) 753-761
33. Doraiswamy, M., Martin, W., Metz, A., Deveaugh Geiss, J.: Psychosis in Parkinson's disease: diagnosis and treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 19 (1995) 835-846
34. Dose, M.: Genehmigungspflicht einer Behandlung mit Clozapin nach Paragraph 1904 des Betreuungsrechts? Nervenarzt 65 (1994) 78-791
35. During, M. J., Freese, A., Deutch, A. Y., Kibat, P. G., Sabel, B. A., Langer, R., Roth, R. H.: Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes. Exp. Neurol. 115 (1992) 193-199
36. During, M. J., Naegele, J. R., O'Malley, K. L., Geller, A. L.: Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266 (1994) 1399-1403
37. Duvall, E., Wyllie, A.: Death and the cell. Immunology Today 7 (1986) 115-119
38. Ellenbroek, B., Prinssen, E., Cools, A.: The azophenothiazine prothipendyl is an atypical neuroleptic acting through D1 and D2 receptors. Neurosci Res Comm 11, 3 (1992) 155-161
39. Factor, S. A., Molho, E. S., Brown, D. L.: Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease. J. Neuropsychiatry. Clin. Neurosci. 7 (1995) 304-307
40. Fernando Pitty, L.: Stereotaxic surgery in Parkinson's disease. A preliminary report of 2 cases. Rev. Med. Panama. 17 (1992) 101
41. Finberg, J. P., Lamensdorff, I., Commissiong, J. W., Youdim, M. B. H.: Pharmacology and neuroprotective properties of rasagiline, J. Neural Transm. Suppl. 48 (1996) 95-102
42. Fox, M. W., Ahlskog, J. E., Kelly, P. J.: Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients. J. Neurosurg. 75 (1991) 723
43. Freed, C. R., Breeze, R. E., Rosenberg, N. L., Schneck, S. A., Wells, T. H., Barrett, J. N., Grafton, S. T., Mazziotta, J. C., Eidelberg, D., Rottenberg, D. A.: Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog. Brain Res. 82 (1990) 715-721
44. Freed, C. R., Breeze, R. E., Rosenberg, N. L., Schneck, S. A., Kriek, E., Qi, J. X., Lone, T., Zhang, Y. B., Snyder, J. A., Wells, T. H. et al: Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327 (1992) 1549-1555
45. Freed, C. R., Breeze, R. E., Rosenberg, N. L., Schneck, S. A.: Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease. Replacing failed nerve terminals. Adv. Neurol. 60 (1993) 721-728
46. Freed, C. R., Breeze, R. E., Schneck, S. A.: Transplantation of fetal mesencephalic tissue in Parkinson's disease. N. Engl. J. Med. 333 (1995) 730-731
47. Freeman, T. B., Olanow, G. W.: Fetal homotransplants in the treatment of Parkinson's disease. Arch. Neurol. 48 (1991) 900-902
48. Freeman, T. B., Olanow, C. W., Hauser, R. A., Nauert, G. M., Smith, D. A., Borlongan, C. V., Sanberg, P. R., Holt, D. A., Kordower, J. H., Vingerhoets, F. J. et al: Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann. Neurol. 38 (1995) 379-388
49. Friedman, J. H. and Lannon, M. C.: Clozapine-responsive tremor in Parkinson's disease. Mov. Disord. 5 (1990) 225-229
50. Fujishiro, K., Hagihara, M., Takahashi, A., Nagatsu, T.: Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson's disease. Biochem. Med. Metab. Biol. 44 (1990) 97-100.
51. Gerlach, M., Kuhn, W., Müller, T., Riederer, P.: Therapeutische Ansätze zur neurodegenerativen Protektion. Aktuelle Neurologie 21 (1994) 151-161
52. Ghika, J.: Initiation of treatment in Parkinson's disease. Schweiz. Rundsch. Med. Prax. 84 (1995) 1018-1020
53. Goetz, C. G., Tanner, C. M., Penn, R. D., Stebbins, G. T., Gilley, D. W., Shannon, K. M., Klawans, H. L., Comella, C. L., Wilson, R. S., Witt, T.: Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology 40 (1990) 273-276
54. Goetz, C. G., Stebbins, G. T., Klawans, H. L., Koller, W. C., Grossman, R. G., Bakay, R. A., Penn, R. D.: United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology 41 (1991) 1719-1722
55. Gonski, P. N.: The use of clozapine in Parkinson's disease. Aust. N. Z. J. Med. 24 (1994) 585
56. Greene, P.: Clozapine therapeutic plunge in patient with Parkinson's disease. Lancet 345 (1995) 1172-1173
57. Gross, R., Amital, D.: Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol. Scand. 91 (1995) 225
58. Guridi, J., Luquin, M. R., Herrero, M. T., Obeso, J. A.: The subthalamic nucleus: A possible target for Stereotaxic surgery in Parkinson's disease. Mov. Disord. 8 (1993) 421-429
59. Hash, C. J., Orr, L. S., Mitchell, I. M.: The return of Stereotaxic surgery. J. Okla. State. Med. Assoc. 82 (1989) 262-264
60. Henderson, B. T., Clough, C. G., Hughes, R. C., Hitchcock, E. R., Kenny, B. G.: Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch. Neurol. 48 (1991a) 822-827
61. Henderson, B. T., Kenny, B. G., Hitchcock, E. R., Hughes, R. C., Clough, C. G.: A comparative evaluation of clinical rating scales and quantitative measurements in assessment pre and post striatal implantation of human foetal mesencephalon in Parkinson's disease. Acta Neurochir. Suppl. Wien. 52 (1991 b) 48-50
62. Hou, J. G., Lin, L. F., Mytilineou, C.: Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neu7ons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J. Neurochem. 66 (1996) 74-82.
63. Hyman, C., Hofer, M., Barde, Y. A., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., Lindsay, R. M.: BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
64. Iacono, R. P., Tang, Z. S., Mazziotta, J. C., Grafton, S., Hoehn, M.: Bilateral fetal grafts for Parkinson's disease: 22 months' results. Stereotact. Funct. Neurosurg. 58 (1992) 84-87
65. Iacono, R. P., Lonser, R. R.: Reversal of Parkinson's akinesia by pallidotomy. Lancet 343 (1994a) 418-419
66. Iacono, R. P., Lonser, R. R., Mandybur, G., Morenski, J. D., Yamada, S., Shima, F.: Stereotactic pallidotomy results for Parkinson's exceed those of fetal graft. Am. Surg. 60 (1994b) 777-782
67. Iacono, R. P., Lonser, R. R., Yamada, S.: Contemporaneous bilateral postero-ventral pallidotomy for early onset "juvenile type" Parkinson's disease. Case report. Acta Neurochir. Wien. 131 (1994c) 247-252
68. Iacono, R. P., Lonser, R. R., Mandybur, G., Yamada, S.: Stimulation of the globus pallidus in Parkinson's disease. Br. J. Neurosurg. 9 (1995) 505-510
69. Iizuka, J.: Controlled single-blind trial of budipine, L-Dopa and amantadine in 102 patients with parkinson's disease. In: F. Gerstenbrand, W. Poewe and G. Stern (Hrsg.): Clinical experience with budipine. Springer, Berlin, Heidelberg, New York 1985, 129
70. Iizuka, J., Fischer, R.: Modification of Parkinson tremor by budipine. A comparative study with amantadine. Nervenarzt. 57 (1986) 184-186
71. Jackisch, R., Huang, H. Y., Reimann, W., Limberger, N.: Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J. Pharmacol. Exp. Ther. 264 (1993) 889-898
72. Jackisch, R., Kruchen, A., Sauermann, W., Hertting, G., Feuerstein, T. J.: The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists. Eur. J. Pharmacol. 264 (1994) 207-211
73. Jansen, E. N.: Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol. Scand. 89 (1994) 262-265
74. Jellinger, K., Bliesath, H.: Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J. Neurol. 234 (1987) 280-282
75. Johansson, M., Friedemann, M., Hoffer, B., Stromberg, I.: Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp. Neurol. 134 (1995) 25-34
76. Kaakkola, S., Gordin, A., Jarvinen, M., Wikberg, T., Schultz, E., Nissinen, E., Pentikainen, P. J., Rita, H.: Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin. Neuropharmacol. 13 (1990) 436-447
77. Kaakkola, S., Gordin, A., Mannisto, P. T.: General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen. Pharmacol. 25 (1994a) 813-824
78. Kaakkola, S., Teravainen, H., Ahtila, S., Rita, H., Gordin, A.: Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44 (1994 b) 77-80
79. Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'-Malley, K. L., During, M. J.: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8 (1994) 148-154
80. Katsube, J., Narabayashi, H., Hayashi, A., Tanaka, C., Suzuki, T.: Development of L-threo-DOPS, a norepinephrine precursor amino acid. Yakugaku. Zasshi. 114 (1994) 823-846
81. Keranen, T., Gordin, A., Harjola, V. P., Karlsson, M., Korpela, K., Pentikainen, P. J., Rita, H., Seppala, L., Wikberg, T.: The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin. Neuropharmacol. 16 (1993) 145-156
82. Klockgether, T., Jacobsen, P., Loschmann, P. A., Turski, L.: The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J. Neural Transm. Park. Dis. Dement. Sect. 5 (1993) 101
83. Kondo, T.: D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia. Rinsho. Shinkeigaku. 24 (1984) 280-288
84. Kondo, T.: L-threo-DOPS in advanced parkinsonism. Adv. Neurol. 60 (1993) 660-665
85. Kordower, J. H., Freeman, T. B., Snow, B. J., Vingerhoets, F.J ., Mufson, E. J., Sanberg, P. R., Hauser, R. A., Smith, D. A., Nauert, G. M., Perl, D. P. et al: Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 332 (1995) 1118-1124
86. Kraus, P., Aubel, T., Wessel, K., Klotz, P., Börnke, C., Langkafel, M. and Przuntek, H.: Anti-tremor effect of prothipendyl (Dominal) in patients with idiopathic tremor-dominant parkinsonian syndrome, J. Neurol. Suppl. 2/242/6 (1995) 740
87. Kuhn, W., Müller, T.: Exogenous stimulation of NGF synthesis by catecholamines and their analogues. J. Neural Transm. Suppl. 46 (1995) 185-188
88. Kuhn, W., Müller, T., Winkel, R., Danielczik, S., Gerstner, A., Häkker, A., Mattern, C., Przuntek, H.: Parenteral application of NADH in Parkinson's disease. Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis, J. Neural. Transm. 103 (1996) 1187-1196
89. Laine, E., Blond, S., Caparros Lefebvre, D.: Novel possibilities for treatment of parkinsonian tremor and other abnormal movements by stimulation of the nucleus ventralis intermedius thalami. Bull. Acad. Natl. Med. 176 (1992) 1147-1156
90. Laitinen, L. V., Bergenheim, A. T., Hariz, M. I.: Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J. Neurosurg. 76 (1992a) 53-61
91. Laitinen, L. V., Bergenheim, A. T., Hariz, M. I.: Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms. Stereotact. Funct. Neurosurg. 58 (1992b) 14-21
92. Laitinen, L. V.: Pallidotomy for Parkinson's disease. Neurosurg. Clin. N. Am. 6 (1995) 105-112
93. Lange, K. W.: Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease. Fortschr. Neurol. Psychiatr. 57 (1989) 142-148
94. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Broussolle, E., Perret, J. E., Benabid, A.L.: Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov. Disord. 10 (1995a) 672-674
95. Limousin, P., Pollak, P., Benazzouz, A., Hoffmann, D., Le Bas, J. F., Broussolle, E., Perret, J. E., Benabid, A. L.: Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345 (1995b) 91-95
96. Limousin, P., Pollak, P., Pfefen, J. P., Tournier-Gervason, C. L., Dubuis, R., Perret, J.: Acute administration of Levodopa-Benserazide and Tolcapone, a COMT inhibitor, in Parkinson's disease. Clin. Neuropharmacol. Suppl 18(3) (1995c) 258-265
97. Lindner, M. D., Winn, S. R., Baetge, E. E., Hammang, J. P., Gentile, F. T., Doherty, E., McDermott, P. E., Frydel, B., Ullman, M. D., Schallert, T. et al: Implantation of encapsulated catecholamine and GDNF-producing cells in rats with unilateral dopamine depletions and parkinsonian symptoms. Exp. Neurol. 132 (1995) 62-76
98. Lindvall, O., Rehncrona, S., Brundin, P., Gustavii, B., Astedt, B., Widner, H., Lindholm, T., Bjorklund, A., Leenders, K. L., Rothwell, J. C. et al: Neural transplantation in Parkinson's disease: the Swedish experience. Prog. Brain Res. 82 (1990) 729-734
99. Lindvall, O.: Cell transplantation: a future therapy for Parkinson's disease? Neurologia. 9 (1994a) 101-107
100. Lindvall, O., Sawle, G., Widner, H., Rothwell, J. C., Bjorklund, A., Brooks, D., Brundin, P., Frackowiak, R., Marsden, C. D., Odin, P. et al: Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann. Neurol. 35 (1994b) 172-180
101. Lindvall, O.: Neural transplantation. Cell Transplant. 4 (1995) 393-400
102. Lloyd, K. G., Davidson, L., Hornykiewicz, O.: The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J. Pharmacol. Exp. Ther. 195 (1975) 453-464
103. Marsden, C. D., Obeso, J. A.: The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain 117 (1994) 877-897
104. Maruyama, W., Naoi, M., Narabayashi, H.: Study on the metabolism of droxidopa in humans. Rinsho. Shinkeigaku. 34 (1994) 991-995
105. Mattern, C: Zur Entwicklung von stabilen Arzneiformen des Coenzyms NADH für die perorale und parenterale Applikation, Humboldt-Universität Berlin, Berlin, 1995
106. McGeer, P. L., McGeer, E. G.: Cholinergic enzyme systems in Parkinson's disease. Arch Neurol 25 (1971) 265-268
107. McRae, A., Hjorth, S., Dahlstrom, A., Dillon, L., Mason, D., Tice, T.: Dopamine fiber growth induction by implantation of synthetic dopamine-containing microspheres in rats with experimental hemi-parkinsonism. Mol. Chem. Neuropathol. 16 (1992) 123-141
108. McRae, A., Dahlstrom, A.: Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OH-DA-induced parkinsonism. Neurochem. Int. 25 (1994) 27-33
109. Meltzer, H. Y.: Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3 (1995a) 64-75
110. Meltzer, H. Y., Kennedy, J., Dai, J., Parsa, M., Riley, D.: Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. A high-potency effect of clozapine. Neuropsychopharmacology. 12 (1995b) 39-45
111. Menge, H., Brand, U.: Zusammenfassende Darstellung der Pharmakologie von Budipin, einem neuen 4,4 Diphenylpiperidinderivat für die Parkinson-Therapie. Drug Res 32 (1982) 85-98
112. Merello, M., Lees, A. J., Webster, R., Bovingdon, M., Gordin, A.: Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57 (1994) 186-189
113. Mihatsch, W., Russ, H., Przuntek, H.: Intracerebroventricular administration of 1-methyl-4-phenylpyridinium ion in mice: effects of simultaneously administered nomifensine, deprenyl, and 1-t-butyl-4,4-diphenylpiperidine. J. Neural Transm. 71 (1988) 177-188
114. Miletich, R. S., Comi, G., Bankiewicz, K., Plunkett, R., Adams, R., Di Chiro, G., Kopin, I. J.: 6-[18F]fluoro-L-dihydroxyphenylalanine metabolism and positron emission tomography after catechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys. Brain Res. 626 (1993) 1-13
115. Mundinger, F., Richert, T.: Die stereotaktischen Hirnoperationen zur Behandlung extrapyramidaler Bewegungsstörungen (Parkinsonismus und Hyperkinesen) und ihre Resultate (Teil A). Fortschr. Neurol. Psychiatr. 63 (1963a) 1-65
116. Mundinger, F., Riechert, T.: Die stereotaktischen Hirnoperationen zur Behandlung extrapyramidaler Bewegungsstörungen (Parkinsonismus und Hyperkinesen) und ihre Resultate (Teil B). Fortschr. Neurol. Psychiatr. 31 (1963b) 69-120
117. Müller, D.: Aktueller Stand der stereotaktischen Therapie beim Parkinson-Syndrom. In: P. A. Fischer (Hrsg.): Parkinson-Krankheit - Bedeutung nichtdopaminerger Funktionsstörungen. Editiones , Basel/Grenzach-Wyhlen, 1994, 235-245
118. Müller, T., Kuhn, W., Gerlach, M., Przuntek, H.: Regenerative Therapie bei neurodegenerativen Erkrankungen. In: G. Huffmann, H. Braune (Hrsg.): Zerebrale und spinale Prozesse. Einhorn-Presse Verlag GmbH, Reinbek, 1996, 350-354
119. Müller, T., Kuhn, W., Przuntek, H.: Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?. J. Neural Transm. Gen. Sect. 92 (1993) 187-195
120. Myllylä, V. V., Sotaniemi, K. A., Illi, A., Suominen, K., Keranen, T.: Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur. J. Clin. Pharmacol. 45 (1993) 419
121. Nagatsu, T., Yamaguchi, T., Rahman, M. K., Trocewicz, J., Oka, K., Hirata, Y., Nagatsu, I., Narabayashi, H., Kondo, T., Iizuka, R.: Catecholamine-related enzymes and the biopterin cofactor in Parkinson's disease and related extrapyramidal diseases. Adv. Neurol. 40 (1984) 467-473
122. Nagatsu, T.: Enzymatic stimulation and enzymatic inhibition in Parkinson's disease. Acta Neurol. Scand. Suppl. 146 (1993) 14
123. Nakajima, Y., Kagamihara, Y., Nagaoka, M., Tanaka, R.: The effect of L-threo-DOPS on synaptic transmission to soleus motoneuron in normal subjects and patients with Parkinson's disease. Neurosci. Res. 5 (1987) 16-27
124. Narabayashi, H.: Mechanism of the development of akinesia in Parkinson's disease - with reference to L-threo-DOPS therapy. No. To. Shinkei. 35 (1983a) 1057-1063
125. Narabayashi, H.: Pharmacological basis of akinesia in Parkinson's disease. J. Neural Transm. Suppl. 19 (1983b) 143-151.
126. Narabayashi, H., Yokochi, F., Ogawa, T., Igakura, T.: Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No. To. Shinkei. 43 (1991) 263-268
127. Nutt, J. G., Woodward, W. R., Beckner, R. M., Stone, C. K., Berggren, K., Carter, J. H., Gancher, S. T., Hammerstad, J. P., Gordin, A.: Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
128. Nuutila, J., Kaakkola, S., Mannisto, P. T.: Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. J. Neural Transm. 70 (1987) 233-240
129. Olanow, C. W., Koller, W., Goetz, C. G., Stebbins, G. T., Cahill, D. W., Gauger, L. L., Morantz, R., Penn, R. D., Tanner, C. M., Klawans, H. L., et al: Autologous transplantation of adrenal medulla in Parkinson's disease. 18-month results. Arch. Neurol. 47 (1990) 1286-1289
130. Oppenheim, R. W., Houenou, L. J., Johnson, J. E., Lin, L. F., Li, L., Lo, A. C., Newsome, A. L., Prevette, D. M., Wang, S.: Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 373 (1995) 344-346
131. Peschanski, M., Defer, G., N'Guyen, J. P., Ricolfi, F., Monfort, J. C., Remy, P., Geny, C., Samson, Y., Hantraye, P., Jeny, R. et al: Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 117 (1994) 487-499
132. Peschanski, M., Cesaro, P., Hantraye, P.: Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68 (1995) 273-285.
133. Pfeiffer, C., Wagner, M. L.: Clozapine therapy for Parkinson's disease and other movement disorders. Am. J. Hosp. Pharm. 51 (1994) 3047-3053.
134. Pillon, B., Dubois, B., Bonnet, A. M., Esteguy, M., Guimaraes, J., Vigouret, J. M., Lhermitte, F., Agid, Y.: Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 39 (1989a) 762-768
135. Pillon, B., Dubois. B., Cusimano, G., Bonnet, A. M., Lhermitte, F., Agid, Y.: Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?. J. Neurol. Neurosurg. Psychiatry 52 (1989b) 201-206
136. price, L. H., Spencer, D. D., Marek, K. L., Robbins, R. J., Leranth, C., Farhi, A., Naftolin, F., Roth, R. H., Bunney, B. S., Hoffer, P. B. et al: Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biol. Psychiatry 38 (1995) 498-505
137. Promonta: Budipin-Kurzprofil, 1994
138. Rabey, J. M., Treves, T. A., Neufeld, M. Y., Orlov, E., Korczyn, A. D.: Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology 45 (1995) 432-434
139. Reches, A., Fahn, S.: Catechol-O-methyltransferase and Parkinson's disease. Adv. Neurol. 40 (1984) 171-179
140. Rich, S. S., Friedman, J. H., Ott, B. R.: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J. Clin. Psychiatry 56 (1995) 556-559
141. Riederer, P., Wuketich, S.: Time course of nigrostriatal degeneration in Parkinson's disease. J. Neural Transm. Gen. Sect. 38 (1976) 277-301
142. Runge, I., Horowski, R.: Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl. J. Neural Transm. Park. Dis. Dement Sect 3 (1991) 273-283
143. Russ, H., Pindur, U., Przuntek, H.: The interaction of 1-alkyl-4,4-diphenylpiperidines with the 1-methyl-4-phenyl-l,2,3,6-tetrahydropyridine receptor binding site. J. Neural Transm. 65 (1986) 157-166
144. Sawada, M., Nagatsu, T., Nagatsu, I., Ito, K., Iizuka, R., Kondo, T., Narabayashi, H.: Tryptophan hydroxylase activity in the brains of controls and parkinsonian patients. J. Neural Transm. 62 (1985) 107-115
145. Sawle, G. V., Burn, D. J., Morrish, P. K., Lammertsma, A. A., Snow, B. J., Luthra, S., Osman, S., Brooks, D. J.: The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease. Neurology 44 (1994) 1292-1297
146. Schaefer, H., Hackmack, G., Eistetter, K., Kruger, U., Menge, H. G. and Klosa, J.: Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines. Arzneimittelforschung. 34 (1984) 233-240
147. Seeman, P.: Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology. 7 (1992) 261-284
148. Spencer, D. D., Robbins, R. J., Naftolin, F., Marek, K. L., Vollmer, T., Leranth, C., Roth, R. H., Price, L. H., Gjedde, A., Bunney, B. S. et al: Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N. Engl. J. Med. 327 (1992) 1541-1548
149. Spieker, S., Löschmann, P., Jentges, C., Boose, A., Klockgether, T., Dichgans, J.: Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin. Neuropharmacol. 18 (3) (1995) 266-272
150. Spina, M. B., Hyman, C., Squinto, S., Lindsay, R. M.: Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann. N. Y. Acad. Sci. 648 (1992a) 348-350
151. Spina, M. B., Squinto, S. P., Miller, J., Lindsay, R. M., Hyman, C.: Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59 (1992b) 99-106
152. Steiler, H.: Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
153. Suter Crazzolara, C., Unsicker, K.: GDNF is expressed in two forms in many tissues outside the CNS. Neuroreport. 5 (1994) 2486-2488
154. Suzuki, T., Sakoda, S., Ueji, M., Kishimoto, S., Hayashi, A., Kondo, T., Narabayashi, H.: Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study. Neurology 34 (1984) 1446-1450
155. Tatton, W. G., Wadia, J. S., In, W. Y. H., Chalmers-Redman, R. M. E., Tatton, N, A.: Deprenyl reduces neuronal apoptosis and faciliates neuronal outgrowth by altering protein synthesis without inhibiting monoamino oxidase, J. Neural Transm. Suppl. 48 (1996) 45-60
156. Thompson, C. B.: Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
157. Tohgi, H., Abe, T., Takahashi, S.: The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 5 (1993) 27-34
158. Tomac, A., Lindqvist, E., Lin, L. F., Ogren, S. O., Young, D., Hoffer, B. J., Olson, L.: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 (1995) 335-339
159. Verhagen Kamerbeek, W. D., Hazemeijer, I., Korf, J., Lakke, J. P.: Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. J. Neural Transm. Park. Dis. Dement. Sect. 6 (1993) 17-26
160. Vrecko, K., Birkmayer, J. G., Krainz, J.: Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adenine dinucleotide (NADH). J. Neural Transm. Park. Dis. Dement. Sect. 5 (1993) 147-156
161. Winn, S. R., Wahlberg, L., Tresco, P. A., Aebischer, P.: An encapsulated dopamine-releasing polymer alleviates experimental parkinsonism in rats. Exp. Neurol. 105 (1989) 244-250
162. Yamaguchi, T., Nagatsu, T., Sugimoto, T., Matsuura, S., Kondo, T., Iizuka, R., Narabayashi, H.: Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease. Science 219 (1983) 75-77
163. Zimmerman, T., Sage, J. I.: Comparison of combination pergolide and levodopa to levodopa alone after 63 months of treatment. Clin. Neuropharmacol. 14 (1991) 165-169